Laikon Hospital, Kapodistriakon University Medical School, Athens, Greece.
Adv Ther. 2009 Mar;26(3):272-80. doi: 10.1007/s12325-009-0009-6. Epub 2009 Mar 2.
Diabetes mellitus (DM) is currently considered to be an epidemic disease. A safe and effective treatment has long been sought by scientists. Incretin mimetics and dipeptidyl peptidase-4 (DPP4) inhibitors represent a new class of agents that have recently been included as antidiabetic drugs. Although only a limited number of studies exist regarding the treatment of DM based on the incretin effect, DPP4 inhibitors have so far proved to be safe and effective, both when administered alone or in combination with other antidiabetic medication. This review focuses on incretin-effect physiology, as well as the DPP4 inhibitors, from sitagliptin to the new alogliptin-pioglitazone combination agent, given as monotherapy and in combination with other antidiabetic agents.
糖尿病（DM）目前被认为是一种流行病。科学家们一直在寻求安全有效的治疗方法。肠促胰岛素类似物和二肽基肽酶-4（DPP4）抑制剂是最近被纳入抗糖尿病药物的一类新型药物。虽然基于肠促胰岛素作用的 DM 治疗只有少数研究，但 DPP4 抑制剂已被证明是安全有效的，无论是单独使用还是与其他抗糖尿病药物联合使用。本综述重点介绍了肠促胰岛素作用的生理学，以及 DPP4 抑制剂，从西他列汀到新的阿格列汀-吡格列酮联合制剂，无论是单独使用还是与其他抗糖尿病药物联合使用。
